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Withdrawal of article by the FDA after objection
from MedtronicThe Journal of Vascular Surgery is the principal vehicle
for disseminating scientific information about new devices
for endovascular aneurysm repair. In April 2003, the Jour-
nal set the precedent of cooperating with the Food and
Drug Administration (FDA) and manufacturers to ensure
timely publication of new data related to device trials simul-
taneous with the initial public release of data by the FDA.
At that time, a peer-reviewed article concerning the Phase
II Medtronic AneuRx study was published,1 with accom-
panying comments by a representative of the FDA2 and the
Editors3 to explain this new initiative. It is therefore with
dismay that the Editors must now report the recent with-
drawal of an accepted article concerning the AneuRx device
by authors from the FDA after strong objections were made
by Medtronic, Inc.
On December 17, 2003, the FDA posted on its Web
site a Public Health Notification entitled “Updated data on
mortality associated with Medtronic AVE AneuRx stent
graft system.”4 On December 24, a scientific manuscript
based on these data was submitted to the Journal by 4
authors from the FDA. This manuscript, entitled
“Aneurysm-related mortality rates in the US AneuRx clin-
ical trial,” underwent peer review and was accepted after
revision on March 18, 2004. After copyediting and author
approval, it was posted in the pre-publication area of the
Journal Web site as an Article in Press on May 7.
On May 20, 2004, the authors contacted the Journal to
request that this accepted article be removed from the
Journal Web site so that changes could be made prior to
print publication. They related that Medtronic Inc had
raised major concerns about the content of the article,
which had prompted a re-review of this submission by the
FDA Center for Devices and Radiologic Health (CDRH),
from which the article originated. Subsequently, on May
21, the Journal was contacted by an attorney at Medtronic
Inc, who alleged that the authors had used confidential and
proprietary data to write the article without the permission
of Medtronic Inc. On the basis of this allegation, the
authors and an attorney for the FDA requested time to
review the entire matter and reiterated their request to
remove the article from the pre-publication area of the
Journal Web site.
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quest to cease and desist unauthorized publication of
Medtronic, Inc’s Confidential Data,” from the law firm
King & Spaulding, LLP, representing Medtronic, Inc. This
letter indicated that Medtronic, Inc strongly objected to
the publication of analyses of post-market approval study
data, which had been submitted to the FDA by Medtronic
under the confidentiality provisions of the Federal Food,
Drug, & Cosmetic Act and the Freedom of Information
Act. The letter also alleged that public release of such
information would constitute both criminal and civil viola-
tions under these acts, and indicated that if the Journal
chose to ignore this request, Medtronic would pursue all
available legal remedies against the Journal and protect its
interests in court if necessary. The letter requested the
immediate removal of the article from the Journal Web site
and assurances against future publication. On the basis of
the seriousness of the allegations of inappropriate publica-
tion of confidential information, and following receipt of a
request by the authors to remove the article, the Editors
and Publisher temporarily removed the article from the
pre-publication area of the Journal Web site on June 8,
2004, pending review by the authors and the FDA of the
accusation made by Medtronic, Inc.
On June 25, 2004, Dr Daniel Schultz, Acting Director
of the CDRH, informed the Journal that the FDA wished
to withdraw the accepted article because the conclusions
drawn in the article went beyond the information provided
in the Public Health Notification4 and, therefore, did not
reflect the FDA’s current position regarding AneuRx-
related mortality. The allegations by Medtronic concerning
inappropriate publication of confidential information were
not addressed. Dr Schultz stated that the FDA was acting
on behalf of the authors who developed the article within
the scope of their employment at the FDA. By this action
the FDA prevented our publication of this article.
The Editors have carefully reviewed the data contained
in this article and compared them with data from the FDA
Public Health Notification of December 17, 2003,4 as well
as an abstract publicly presented by the authors at the 2004
FDA Science Forum.5 It is our conclusion that the data
submitted to the Journal, and alleged to be confidential by
Medtronic, Inc, are identical to the data in these other
public documents. In these documents, the FDA analyzed
aneurysm-related deaths in 942 patients from the Phase II
trial who received the flexible AneuRx graft currently mar-209
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of 1.5% and thereafter an annualized aneurysm-related
mortality rate of 0.4% per year. They estimated the cumu-
lative aneurysm-related mortality to be 2.7% at 3 years after
implant.4 Furthermore, the FDA concluded that the risk of
late aneurysm-related mortality associated with the AneuRx
stent-graft system may exceed that associated with open
surgery in some institutions, and that the overall aneurysm-
associated mortality from the AneuRx stent graft is likely to
cross over and exceed the aneurysm-associated mortality
from open surgery at some point in time.4 They encour-
aged surgeons to carefully consider patient risk factors,
including the risk of subsequent events, when recommend-
ing open versus endovascular repair.
On the basis of this analysis, the objection to publica-
tion of these data in the Journal by Medtronic Inc can
hardly be attributed to confidentiality concerns. The data
have been publicly available since December, although few
vascular surgeons may have seen them. We can only spec-
ulate about the motivation for Medtronic’s actions. The
results do not appear inferior to other published reports
concerning aneurysm-related mortality following endovas-
cular repair, but perhaps they were interpreted that way. In
addition, the explanation by the FDA that the conclusions
in the article go beyond the Public Health Notification
cannot apply to the data, which were identical, but rather
must apply to interpretations and discussion by the authors,which we regard as appropriate scientific discourse. This
action taken in response to objections by a manufacturer of
a device regulated and approved by the FDA is very disturb-
ing.
The Editors are extremely disappointed by the actions
of the FDA and Medtronic Inc, which have prevented the
publication of an article containing data that we believe are
important to readers of the Journal. We encourage readers
to make themselves aware of the data concerning aneu-
rysm-related mortality concerning the AneuRx stent graft
that are available on the FDA Web site.4,5
Jack L. Cronenwett, MD
James M. Seeger, MD
Editors
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